Kinase Inhibitors and Kinase-Targeted Cancer Therapies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 144
Special Issue Editor
Special Issue Information
Dear Colleagues,
The advent of targeted therapies has revolutionized the clinical management of cancer by providing alternatives to the use of systematically toxic chemotherapy and locally damaging radiotherapy. Kinase inhibitors comprise an important part of this new arsenal and are now used in first-line therapy in bespoke cancer settings. Historically, these inhibitors have been reversible ATP competitors, often suffering from a lack of selectivity and being rapidly counteracted by the development of drug resistance. However, novel classes of inhibitors have now emerged, showing drastically improved selectivity (including to particular mutational states of their targets) and pharmacodynamic properties, including irreversible binding. Additionally, alternative mechanisms of action that avoid targeting the ATP binding sites, such as allosteric modulation or degradation, have further improved selectivity amongst phylogenetically related targets and enabled the circumvention of traditional resistance pathways.
This Special Issue of IJMS is calling for both original articles and reviews that present novel findings and summative assessments of advances in kinase inhibition.
Dr. Olivier E. Pardo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kinase activity inhibitors
- degraders
- antibodies
- nanobodies
- protein–kinase interaction inhibitors
